Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have received a consensus rating of “Hold” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $18.50.

A number of research firms have weighed in on ANGO. Canaccord Genuity reiterated a “hold” rating and issued a $16.50 target price on shares of AngioDynamics in a research note on Wednesday, May 31st. KeyCorp reiterated a “hold” rating on shares of AngioDynamics in a research note on Friday, August 25th. Cantor Fitzgerald boosted their target price on shares of AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. Zacks Investment Research cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th. Finally, BidaskClub cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st.

AngioDynamics (NASDAQ:ANGO) traded up 0.29% on Wednesday, reaching $17.44. 224,759 shares of the company’s stock traded hands. The stock has a market cap of $637.96 million, a price-to-earnings ratio of 127.30 and a beta of 1.14. The company’s 50 day moving average is $16.53 and its 200-day moving average is $16.22. AngioDynamics has a 52-week low of $14.80 and a 52-week high of $18.35.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. The firm had revenue of $86.90 million for the quarter, compared to analysts’ expectations of $90.72 million. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The company’s quarterly revenue was down 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.19 earnings per share. Equities analysts expect that AngioDynamics will post $0.67 EPS for the current year.

In other AngioDynamics news, CEO James C. Clemmer purchased 20,000 shares of the stock in a transaction dated Thursday, July 20th. The shares were bought at an average price of $15.64 per share, with a total value of $312,800.00. Following the completion of the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,355,722.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Clemmer purchased 5,000 shares of the stock in a transaction dated Friday, July 21st. The stock was acquired at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,368,724.57. The disclosure for this purchase can be found here. In the last three months, insiders bought 25,316 shares of company stock worth $396,806. Insiders own 1.88% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of AngioDynamics by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 3,128,777 shares of the medical instruments supplier’s stock valued at $54,285,000 after purchasing an additional 14,823 shares during the period. Vanguard Group Inc. raised its position in shares of AngioDynamics by 14.4% in the second quarter. Vanguard Group Inc. now owns 1,938,115 shares of the medical instruments supplier’s stock valued at $31,416,000 after purchasing an additional 243,825 shares during the period. Broadfin Capital LLC raised its position in shares of AngioDynamics by 14.9% in the second quarter. Broadfin Capital LLC now owns 1,683,252 shares of the medical instruments supplier’s stock valued at $27,286,000 after purchasing an additional 217,800 shares during the period. Northern Trust Corp raised its position in shares of AngioDynamics by 14.9% in the second quarter. Northern Trust Corp now owns 1,202,941 shares of the medical instruments supplier’s stock valued at $19,500,000 after purchasing an additional 155,951 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of AngioDynamics by 86.3% in the second quarter. Wells Fargo & Company MN now owns 1,015,594 shares of the medical instruments supplier’s stock valued at $16,463,000 after purchasing an additional 470,522 shares during the period. 95.80% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/06/angiodynamics-inc-ango-given-consensus-recommendation-of-hold-by-brokerages.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.